Sobi, a prominent biopharmaceutical company, is set to acquire Arthrosi Therapeutics, a biotechnology firm focused on gout treatments, for an initial payment of $950...
Cytokinetics has announced that its cardiac myosin inhibitor, aficamten, may redefine the standard of care for patients with heart muscle disorders. This revelation came...